First patient dosed in Racura’s HARNESS-1 trial of RC220
The first patient was treated at Monash Health in Clayton, Victoria, Australia, with other trial sites planned in the near future.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance